Literature DB >> 29223100

Activation of anti-oxidant Nrf2 signaling by enone analogues of curcumin.

Lorraine M Deck1, Lucy A Hunsaker2, Thomas A Vander Jagt2, Lisa J Whalen3, Robert E Royer2, David L Vander Jagt2.   

Abstract

Inflammation and oxidative stress are common in many chronic diseases. Targeting signaling pathways that contribute to these conditions may have therapeutic potential. The transcription factor Nrf2 is a major regulator of phase II detoxification and anti-oxidant genes as well as anti-inflammatory and neuroprotective genes. Nrf2 is widespread in the CNS and is recognized as an important regulator of brain inflammation. The natural product curcumin exhibits numerous biological activities including ability to induce the expression of Nrf2-dependent phase II and anti-oxidant enzymes. Curcumin has been examined in a number of clinical studies with limited success, mainly owing to limited bioavailability and rapid metabolism. Enone analogues of curcumin were examined with an Nrf2 reporter assay to identify Nrf2 activators. Analogues were separated into groups with a 7-carbon dienone spacer, as found in curcumin; a 5-carbon enone spacer with and without a ring; and a 3-carbon enone spacer. Activators of Nrf2 were found in all three groups, many of which were more active than curcumin. Dose-response studies demonstrated that a range of substituents on the aromatic rings of these enones influenced not only the sensitivity to activation, reflected in EC50 values, but also the extent of activation, which suggests that multiple mechanisms are involved in the activation of Nrf2 by these analogues.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Aldol condensation; Enone; Nrf2 activation; Pyridone

Mesh:

Substances:

Year:  2017        PMID: 29223100     DOI: 10.1016/j.ejmech.2017.11.048

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  17 in total

1.  Development of a cell-based pathway modulator screening system to screen the targeted cancer therapeutic candidates.

Authors:  Ponmathi Panneerpandian; Kumaresan Ganesan
Journal:  Hum Cell       Date:  2021-01-06       Impact factor: 4.174

2.  Curcumin sensitizes carboplatin treatment in triple negative breast cancer through reactive oxygen species induced DNA repair pathway.

Authors:  Genjin Wang; Peng Duan; Zhengkuo Wei; Feng Liu
Journal:  Mol Biol Rep       Date:  2022-01-25       Impact factor: 2.316

Review 3.  Curcumin in Health and Diseases: Alzheimer's Disease and Curcumin Analogues, Derivatives, and Hybrids.

Authors:  Eirini Chainoglou; Dimitra Hadjipavlou-Litina
Journal:  Int J Mol Sci       Date:  2020-03-13       Impact factor: 5.923

4.  Curcumin attenuates Adriamycin-resistance of acute myeloid leukemia by inhibiting the lncRNA HOTAIR/miR-20a-5p/WT1 axis.

Authors:  Jun-Min Liu; Min Li; Wei Luo; Hong-Bo Sun
Journal:  Lab Invest       Date:  2021-07-19       Impact factor: 5.502

5.  Synthesis and Biological Evaluations of Monocarbonyl Curcumin Inspired Pyrazole Analogues as Potential Anti-Colon Cancer Agent.

Authors:  Zhenli Min; Yue Zhu; Xing Hong; Zhijun Yu; Min Ye; Qiong Yuan; Xiamin Hu
Journal:  Drug Des Devel Ther       Date:  2020-06-29       Impact factor: 4.162

6.  Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells.

Authors:  Shan Hu; Yingchun Xu; Liwei Meng; Liming Huang; He Sun
Journal:  Exp Ther Med       Date:  2018-06-22       Impact factor: 2.447

7.  Synthesis of new curcumin-based aminocarbonitrile derivatives incorporating 4H-pyran and 1,4-dihydropyridine heterocycles.

Authors:  Soheila Khajeh Dangolani; Farhad Panahi; Ali Khalafi-Nezhad
Journal:  Mol Divers       Date:  2020-05-17       Impact factor: 2.943

8.  Aromatic-Turmerone Analogs Protect Dopaminergic Neurons in Midbrain Slice Cultures through Their Neuroprotective Activities.

Authors:  Yuria Hori; Reiho Tsutsumi; Kento Nasu; Alex Boateng; Yasuhiko Ashikari; Masaharu Sugiura; Makoto Nakajima; Yuki Kurauchi; Akinori Hisatsune; Hiroshi Katsuki; Takahiro Seki
Journal:  Cells       Date:  2021-05-03       Impact factor: 6.600

Review 9.  Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer.

Authors:  Namrata Khurana; Suresh C Sikka
Journal:  Cancers (Basel)       Date:  2018-09-25       Impact factor: 6.639

Review 10.  Emerging Screening Approaches in the Development of Nrf2-Keap1 Protein-Protein Interaction Inhibitors.

Authors:  Chung-Hang Leung; Jia-Tong Zhang; Guan-Jun Yang; Hao Liu; Quan-Bin Han; Dik-Lung Ma
Journal:  Int J Mol Sci       Date:  2019-09-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.